drugset / Trial / NCT04562428

The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial

NCT04562428 ↗

Phase 4 Completed 10 enrolled China Medical University Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study was search the safety and efficacy of the of Xiang Sha Liu Jun Zi Decoction (XSLJZ) in advanced hepatocellular carcinoma patients with multiple protein kinase inhibitor therapy. Evaluate the treatment effect on the symptoms of appetite and quality of life in advanced hepatocellular carcinoma patients

Timeline

Start
2020-11-20
Primary completion
2020-12-31
Completion
2023-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Xiang Sha Liu Jun Zi Decoction Traditional medicine (herbal / TCM) 7.5 g —